Bristol Backs Out Of Pierre Fabre Collaboration For Vinflunine
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol had positioned the investigational bladder cancer drug as part of a strategy to recapture leadership in oncology through development of novel cytotoxics.